Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fonc.2015.00186 http://scihub22266oqcxt.onion/10.3389/fonc.2015.00186 C4538302!4538302!26347853     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Front+Oncol 2015 ; 5 (ä): ä Nephropedia Template TP {{tp|p=26347853|t=2015. Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy |pdf=|usr=}}{{26347853}} gab.com Text Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy JO: Front Oncol http://www.kidney.de/pget.php?&tw=1&pmid=26347853 #FOAvip Epithelioid sarcoma (ES) is a soft tissue sarcoma of children and young adults for which the preferred treatment for localized disease is wide surgical resection. Medical management is to a great extent undefined, and therefore for patients with regional and distal metastases, the development of targeted therapies is greatly desired. In this review, we will summarize clinically relevant biomarkers (e.g., SMARCB1, CA125, dysadherin, and others) with respect to targeted therapeutic opportunities. We will also examine the role of EGFR, mTOR, and polykinase inhibitors (e.g., sunitinib) in the management of local and disseminated disease. Toward building a consortium of pharmaceutical, academic, and non-profit collaborators, we will discuss the state of resources for investigating ES with respect to cell line resources, tissue banks, and registries so that a roadmap can be developed toward effective biology-driven therapies. Twit Text FOAVip Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy ????Front Oncol http://www.kidney.de/pget.php?&tw=1&pmid=26347853 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26347853 #FOAvip English Wikipedia <ref>{{Cite pmid|26347853}}</ref> Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy #MMPMID26347853 Noujaim J; Thway K; Bajwa Z; Bajwa A; Maki RG; Jones RL; Keller C Front Oncol 2015[]; 5 (ä): ä PMID26347853show ga Epithelioid sarcoma (ES) is a soft tissue sarcoma of children and young adults for which the preferred treatment for localized disease is wide surgical resection. Medical management is to a great extent undefined, and therefore for patients with regional and distal metastases, the development of targeted therapies is greatly desired. In this review, we will summarize clinically relevant biomarkers (e.g., SMARCB1, CA125, dysadherin, and others) with respect to targeted therapeutic opportunities. We will also examine the role of EGFR, mTOR, and polykinase inhibitors (e.g., sunitinib) in the management of local and disseminated disease. Toward building a consortium of pharmaceutical, academic, and non-profit collaborators, we will discuss the state of resources for investigating ES with respect to cell line resources, tissue banks, and registries so that a roadmap can be developed toward effective biology-driven therapies. äEpithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy(epmc).pdf DeepDyve Pubget Overpricing